ZYME: Options Surge to 52-Week High as Shorts Build Into November Print

Short positioning reinforces the cautious read, though without the same urgency. Short interest climbed 4.2% on the week to 6.8% of the free float, roughly 5.1 million shares, and has risen about 11% over the past month. The pace is steady rather than aggressive. Borrowing costs remain low at 0.60%, up 49% on the week but still in a range that suggests no squeeze dynamic. Availability is ample at 440%, meaning there are more than four shares available to borrow for every share already lent out. The ORTEX short score moved to 58.3 on Tuesday, a new high for the recent series, but still well short of extreme territory. Taken together, the positioning looks cautious rather than crowded.

The Street, by contrast, is broadly constructive and has been nudging targets higher. All 12 analysts tracked carry buy-equivalent ratings. Truist Securities raised its target to $34 this week, and Citigroup moved to $39 late last month. Wolfe Research initiated coverage with an Outperform in September. The consensus mean target is $41.07, implying roughly 60% potential return from the current price of $25.65. The analyst rec differential factor ranks in the 97th percentile, one of the stronger conviction readings in the biotech universe. The bull case rests on zanidatamab's FDA-approved label in first-line HER2-positive gastroesophageal cancer, Phase 3 data showing median progression-free survival of 12.4 versus 8.1 months, a $250 million milestone payment, and royalties that could step up to 20% on sales above $2 billion. Bears counter that commercial uptake is uncertain, execution risk on the broader pipeline is high, and the stock carries dilution overhang if additional financing becomes necessary.

The ownership structure is dominated by a single activist. EcoR1 Capital holds 30.7% of the company and has filed seven Schedule 13D amendments since first disclosing in December 2024, the most recent in November 2025. An active 13D holder at that scale is one of the more consequential facts about the stock: EcoR1 is not a passive bystander to corporate strategy. Rubric Capital sits at 9.5% and Perceptive Advisors at 5.9%, the latter having built its entire position in Q1 2026. Stakes are as last disclosed around the 5% threshold; a holder dropping below 5% may exit without a further filing. Wikipedia attention for Zymeworks is running about 1.7 standard deviations above its own 90-day baseline, suggesting a pickup in retail interest that coincides with the recent negative price action.

Correlated peers have had a rough week. IMNM fell 11.8% and IMTX dropped 12.4%. SANA is down 5.5% and SRPT off 7.1%. ZYME itself has fallen 5.7% on the week to $25.65, so the stock is not uniquely weak, but it is also not holding up relative to peers. The prior two earnings prints produced a 4.5% one-day gain in August 2026 and a 13.5% one-day drop in May 2026, a wide range that underlines how much the next print matters.

With 30 days to go before the Q3 release, the tension worth watching is whether the put/call ratio at its 52-week high reflects genuine concern about the commercial ramp of zanidatamab, or simply hedging against a biotech sector that has been broadly weak. If the PCR retreats as the date approaches, that would suggest the current defensiveness is noise. If it holds or climbs further while short interest continues its gradual build, the setup into November becomes notably more charged.